Dec 15, 2025 • Investing.com
BULLISH
Roivant Sciences stock hits all-time high at 22.45 USD
Roivant Sciences stock (ROIV) has reached an all-time high of $22.45, reflecting strong investor confidence with its stock rising 86.66% over the past year and 95.23% in the last six months. The biotechnology company, with a market capitalization of $15.57 billion and more cash than debt, has received positive analyst updates and accelerated timelines for key drug candidates like brepocitinib. Despite concerns that the stock might be trading above its Fair Value, analysts maintain price targets ranging up to $33, indicating potential for further growth.
Dec 15, 2025 • Barchart.com
SOMEWHAT-BULLISH
Alzheimer’s Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Biogen, Eisai, Eli Lilly and Company, AB Science, Alzheon, Inc., Cerecin, BioVie, Eisai Inc
The Alzheimer’s Disease market is projected to reach approximately USD 5,038 million in 2025 and grow significantly by 2034, driven by increasing prevalence, awareness, and the launch of numerous pipeline products. Key companies like Biogen, Eisai, and Eli Lilly are advancing new therapies, including subcutaneous injections and novel antibodies, with several recent FDA designations and positive clinical trial results highlighting the robust development landscape. The growing patient population, particularly in the US and Japan, underscores the urgent need and market potential for effective treatments.
Dec 15, 2025 • openPR.com
SOMEWHAT-BULLISH
Alzheimer's Disease Market to Experience Notable Growth
The Alzheimer's Disease market is projected to grow significantly, driven by increasing prevalence, awareness, and the launch of new pipeline products. DelveInsight predicts the market size to reach approximately USD 5,038 million in 2025 and grow at a CAGR of 23.7% through 2034, with key companies like Biogen, Eisai, and Eli Lilly leading the development of new therapies. The report also highlights recent clinical advancements and the rising number of diagnosed cases, particularly in the US and Japan.
Dec 15, 2025 • MarketBeat
NEUTRAL
Marex Group plc Purchases Shares of 65,461 Pfizer Inc. $PFE
Marex Group plc acquired a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, purchasing 65,461 shares valued at approximately $1.59 million. Other institutional investors like Ossiam and Strs Ohio also increased their holdings, bringing total institutional ownership to 68.36%. Analysts currently maintain a consensus "Hold" rating for Pfizer, with an average price target of $28.33, while the company anticipates FY2025 EPS guidance between $3.00 and $3.15.
Dec 15, 2025 • MarketBeat
NEUTRAL
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE
Cullen Capital Management LLC has significantly reduced its stake in Pfizer Inc. by 22.9%, now holding shares valued at $88.32 million. Despite this reduction, other institutional investors have increased their positions in Pfizer. The company recently reported strong quarterly earnings, beating EPS estimates, and declared a quarterly dividend of $0.43 per share.
Dec 15, 2025 • Finviz
NEUTRAL
Eli Lilly Just Delivered Fantastic News to Investors
Eli Lilly announced promising phase 3 trial results for its weight loss candidate, retatrutide, showing an average weight loss of over 28% in patients with obesity and knee osteoarthritis. This performance is a leading result among weight loss drugs, positioning Eli Lilly strongly in the potentially $100 billion weight loss market. The company has several more retatrutide trial readouts expected in 2026, offering future catalysts for the stock.